Research Analysts Offer Predictions for Bruker Q1 Earnings

Bruker Co. (NASDAQ:BRKR - Free Report) - Analysts at Leerink Partnrs boosted their Q1 2025 EPS estimates for shares of Bruker in a research report issued on Wednesday, April 16th. Leerink Partnrs analyst P. Souda now expects that the medical research company will post earnings of $0.50 per share for the quarter, up from their prior forecast of $0.41. The consensus estimate for Bruker's current full-year earnings is $2.69 per share. Leerink Partnrs also issued estimates for Bruker's Q2 2025 earnings at $0.54 EPS, Q3 2025 earnings at $0.65 EPS, Q4 2025 earnings at $0.87 EPS, FY2025 earnings at $2.55 EPS, Q1 2026 earnings at $0.64 EPS, Q2 2026 earnings at $0.63 EPS, Q3 2026 earnings at $0.71 EPS, Q4 2026 earnings at $0.94 EPS, FY2026 earnings at $2.92 EPS and FY2027 earnings at $3.38 EPS.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its earnings results on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, beating analysts' consensus estimates of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%.

Several other equities analysts have also recently issued reports on the stock. Barclays dropped their price objective on shares of Bruker from $60.00 to $50.00 and set an "overweight" rating on the stock in a research note on Thursday, April 10th. Stifel Nicolaus reduced their target price on Bruker from $70.00 to $57.00 and set a "hold" rating for the company in a report on Friday, February 14th. Guggenheim reaffirmed a "buy" rating on shares of Bruker in a research note on Monday, February 24th. Citigroup decreased their price target on shares of Bruker from $75.00 to $50.00 and set a "buy" rating on the stock in a research note on Monday, April 7th. Finally, Wells Fargo & Company cut their price target on Bruker from $75.00 to $60.00 and set an "overweight" rating for the company in a report on Thursday, April 17th. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, Bruker has a consensus rating of "Moderate Buy" and an average price target of $65.00.

Bruker Stock Performance

Bruker stock traded up $1.49 during mid-day trading on Friday, reaching $38.45. 1,022,517 shares of the company were exchanged, compared to its average volume of 1,504,639. The firm's 50-day simple moving average is $43.92 and its two-hundred day simple moving average is $53.25. Bruker has a twelve month low of $34.10 and a twelve month high of $83.32. The firm has a market cap of $5.83 billion, a PE ratio of 50.59, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60.

Bruker Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, March 28th. Investors of record on Monday, March 17th were given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.52%. The ex-dividend date was Monday, March 17th. Bruker's dividend payout ratio (DPR) is presently 26.32%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Wealthquest Corp purchased a new position in shares of Bruker in the 1st quarter valued at $143,000. Lecap Asset Management Ltd. acquired a new position in shares of Bruker during the first quarter worth about $2,714,000. Rakuten Securities Inc. purchased a new stake in shares of Bruker in the first quarter worth about $167,000. Wealth Enhancement Advisory Services LLC grew its stake in shares of Bruker by 81.2% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 29,826 shares of the medical research company's stock valued at $1,245,000 after buying an additional 13,367 shares in the last quarter. Finally, Fifth Third Bancorp lifted its position in Bruker by 54.2% during the 1st quarter. Fifth Third Bancorp now owns 1,109 shares of the medical research company's stock worth $46,000 after acquiring an additional 390 shares in the last quarter. 79.52% of the stock is owned by institutional investors and hedge funds.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.